m+Medelevator.RU
← Поиск публикаций
Biochemistry and biophysics reports · 2025

miR-628-3p exerts a carcinogenic effect on hepatocellular carcinoma.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Liu Lele, Cheng Ziyi, Liu Dina, Pan Mingang, Luo Muyu, Chen Yunmeng, Xia Jie

Аннотация

Hepatocellular carcinoma (HCC) is associated with the highest mortality rate among various types of liver tumors. miR-628-3p, a microRNA, has been identified as a tumor suppressor in multiple cancer types, yet its function in hepatocellular carcinoma has not been investigated. This study aimed to examine the effect of miR-628-3p on the occurrence and development of HCC and its specific molecular mechanism. Here, we evaluated the effect of miR-628-3p on HCC proliferation by using in vitro proliferation assays and a xenograft tumor model. Flow cytometry was used to monitor the cell cycle and apoptosis of HCC cells. Reverse Transcription-Quantitative Polymerase Chain Reaction (RT-qPCR) and Western blot (WB) were used to determine the expression of each gene. Our study showed that miR-628-3p levels decrease in HCC, and its overexpression can enhance cell proliferation and cell cycle progression while suppressing apoptosis. Examination of the gene expression profiles of MHCC9H cells with miR-628-3p overexpression shows that cancer-promoting pathways like hypoxia and Notch signaling are upregulated. Meanwhile, miR-628-3p overexpression inhibits tumor suppressor pathways such as apoptosis and p53 signaling. miR-628-3p affects the cell cycle and apoptosis of HCC through the p53 pathway. Moreover, the expression of miR-628-3p is regulated by p53 to some extent. Our findings suggest that miR-628-3p has a tumor-promoting effect on HCC and that miR-628-3p inhibitors may be a new therapeutic approach for HCC.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты